A new study reveals the molecular and cellular mechanisms behind why some people find it harder to stop using antidepressants than others with depression.
Psilocybin, the psychoactive compound found in magic mushrooms, is as effective at treating depression as conventional SSRI antidepressants. Researchers report, that although not significantly significant, early findings reveal those treated with psilocybin experienced more rapid and greater reductions in depression symptoms than those treated with SSRIs.
A mouse study refutes the common belief that psilocybin's ability to produce an anti-depressant effect is attributed to the psychedelic experience it creates. Blocking the psychedelic effect did not affect psilocybin's anti-depressant effects.
With the risk of potential for abuse, some new fast-acting antidepressants, like Ketamine, may not be a magic "cure-all" for depression.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Study reveals a link between people with depression who are prescribed newer antipsychotic medications and higher mortality risk.
Researchers have uncovered the structure of psychedelic compounds when they actively bind to the 5-HT2A serotonin receptor on the surface of brain cells. The discovery could lead to the exploration of more precise compounds that offer the therapeutic effects of psychedelics for mental health disorders, but without the hallucinations.
Activity of the c-Fos gene begins the increase on the ninth day of exposure to antidepressants. By day 14, mice showed behavioral changes associated with SSRI use. This may explain why suicide rates drop after nine days of treatment, and symptoms of depression improve after three weeks.